JariAandelen schreef op 10 oktober 2014 10:31:
PHARM: Salix & Salespeople; Management Views; Reiterate Buy
Print Friendly
Biotech company Pharming Group NV announces the analyst report completed by Joseph Pantginis, Ph.D. from Roth Capital Partners is published.
Salix (SLXP-Buy) salespeople are actively being trained to sell Ruconest, which is expected to launch in 4Q14. PHARM management is therefore not concerned that any potential merger between Salix and Allergan (AGN-NC) would impact launch. We continue to focus on the ongoing study of Ruconest in HAE prophylaxis, as we believe positive data could lead to interest from Salix to acquire PHARM outright based on the larger prophylaxis market. Reiterate Buy.